Form 4 for URGN UroGen Pharma Ltd.
Accepted 2024-09-12 00:00:00 ET · period of report 2024-09-09 · accession 0001437749-24-029036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-12 | 2024-09-09 | URGN | Kim Dong | CFO | M - OptEx | — | +2,500 | 37.8K | +7% | — |
| D | 2024-09-12 | 2024-09-09 | URGN | Kim Dong | CFO | M - OptEx | $0.00 | -2,500 | 5,000 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-09-09 | M | A | 2,500 | — | 37,753 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. |
| 2 | Derivative | Restricted Stock Units | 2024-09-09 | M | D | 2,500 | $0.00 | 5,000 | D | — · — to — | 2,500 Ordinary Shares | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. (F2) The reporting person was granted RSUs on September 7, 2023 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. |